Alethia Biotherapeutics Closes C$9.6M Series A Round of Financing
Alethia Biotherapeutics Inc., a developer of monoclonal antibodies for the treatment and prevention of severe bone loss, ovarian cancer and metastatic breast cancer, closed a C$9.6M Series A round of financing. The Montreal-based company will use the funds to advance its lead pre-clinical programs into clinical development. AgeChem Venture Fund, BDC Venture Capital and GO Capital Fund participated in the round.
7 September 2010•4 mins read
